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Abstract
Previous studies have suggested that probiotic fermented milk may possess blood pressure (BP)-lowering properties. In the present
study, we aimed to systematically examine the effect of probiotic fermented milk on BP by conducting a meta-analysis of randomised
controlled trials. PubMed, Cochrane library and the ClinicalTrials.gov databases were searched up to March 2012 to identify eligible studies.
The reference lists of the obtained articles were also reviewed. Either a fixed-effects or a random-effects model was used to calculate
the combined treatment effect. Meta-analysis of fourteen randomised placebo-controlled trials involving 702 participants showed that
probiotic fermented milk, compared with placebo, produced a significant reduction of 3·10 mmHg (95 % CI 24·64, 21·56) in systolic
BP and 1·09 mmHg (95 % CI 22·11, 20·06) in diastolic BP. Subgroup analyses suggested a slightly greater effect on systolic BP in hyper-
tensive participants than in normotensive ones (23·98 v. 22·09 mmHg). Analysis of trials conducted in Japan showed a greater reduction
than those conducted in European countries for both systolic BP (26·12 v. 22·08 mmHg) and diastolic BP (23·45 v. 20·52 mmHg). Some
evidence of publication bias was present, but sensitivity analysis excluding small trials that reported extreme results only affected the
pooled effect size minimally. In summary, the present meta-analysis suggested that probiotic fermented milk has BP-lowering effects
in pre-hypertensive and hypertensive subjects.
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Fermented milk, such as yogurt and cultured soured milk, has
been considered as a functional food and widely consumed
over the world for centuries. Fermented milk is a product
obtained from the fermentation of milk by the action of
suitable micro-organisms and the resultant reduction of
pH with or without coagulation (isoelectric precipitation).
The commonly used micro-organisms for the fermentation
process include Streptococcus thermophilus, Lactobacillus
delbrueckii subsp. bulgaricus, Lactobacillus acidophilus
and Lactobacillus kefiri. Today, other micro-organisms are
increasingly being used to produce fermented milk. Since
this fermented milk has been shown to have a number
of pleiotropic health benefits, it may be referred to as pro-
biotic fermented milk(1). Evidence from large prospective
cohort studies has suggested that probiotic fermented milk
may exert protective effects against many chronic diseases,
including type 2 diabetes(2), CVD(3) and stroke(4). Also,
a recent meta-analysis of clinical trials has reported that
consumption of probiotic yogurt significantly lowers total
cholesterol and LDL-cholesterol concentrations(5). However,
a number of clinical trials investigating the effect of probiotic
fermented milk on blood pressure (BP) have yielded mixed
results(6–18). These inconsistent findings may result from
differences in sample size, study intervention, study popu-
lation or study quality, and therefore a clear view on the
overall impact of probiotic fermented milk on BP is difficult
to obtain. Thus, in the present study, we aimed to syste-
matically examine the effect of probiotic fermented milk
on BP by conducting a meta-analysis of randomised con-
trolled trials.
*Corresponding authors: L.-Q. Qin, email qinliqiang@suda.edu.cn; Y. Zhao, fax þ86 10 5987 1301, email youyou.zhao@rd.nestle.com
Abbreviation: BP, blood pressure.
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Experimental methods
Literature search
We followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines in the
report of this meta-analysis(19). We conducted an electronic
search of PubMed, Cochrane library and the ClinicalTrials.gov
databases up to March 2012 for relevant studies. Search terms
included ‘yogurt’, ‘yoghurt’, ‘sour milk’, ‘fermented milk’, ‘pro-
biotic’, ‘blood pressure’ and ‘hypertension’. Reference lists in
the retrieved articles obtained from the electronic search
were also manually scanned.
Study selection
Studies were included if they (1) were randomised, placebo-
controlled trials, (2) used probiotic fermented milk as the
intervention product and (3) reported the net changes in BP
and the associated standard deviations (or data to calculate
them). Because we aimed to examine the effect of probiotic
fermented milk, studies using enzymatically hydrolysed milk
as the intervention product were excluded. We also excluded
studies that had a co-intervention of other supplementations
or were duplicate reports from the same trial.
Data extraction and quality assessment
The following characteristics of each study were recorded: first
author’s last name, publication year and country of origin;
design details, including whether parallel or cross-over and
open label, single blind or double blind; treatment duration;
daily dose of probiotic fermented milk. Participant character-
istics including age, sex, baseline BP and antihypertensive
medication use were also recorded. If more than one
time point for follow-up was reported, we used the data
from the longest follow-up time period. Similarly, we used
the data from the highest dose when there was more than
one single dose for the intervention. One study included
two independent strata (hypertensive and normotensive)
and was subsequently treated as two trials(7).
Study quality was assessed in terms of randomisation,
allocation concealment, blinding, description of withdrawals
and availability of intention-to-treat analysis.
Statistical analysis
In parallel trials, the net effect of probiotic fermented milk on
BP was calculated as the difference in mean systolic BP and
diastolic BP change between the intervention and control
groups. In cross-over trials, the effect of probiotic fermented
milk was calculated as the difference in BP between the
intervention and control periods. Studies that did not report
standard deviation values had these values imputed from
standard errors, CI or P values using a standard formula(20).
The between-study heterogeneity was tested using
Cochran’s Q test at the P,0·10 level of significance. The I 2
statistic, a quantitative measure of inconsistency across
studies, was also calculated(21). Either a fixed-effects or, in
the presence of heterogeneity, a random-effects model was
used to calculate the pooled effect size.
To explore the possible influences of study designs and par-
ticipant characteristics on combined effect sizes, we further
conducted pre-specified subgroup analyses stratified by
hypertension status, study location and duration of inter-
vention. To test the robustness of the results, we performed
sensitivity analyses limited to parallel trials, double-blind
trials and trials in which participants did not use antihyper-
tensive medications. In addition, we repeated the analyses
by omitting one trial in each turn to investigate the influence
of a single trial on the overall effect estimate.
Potential publication bias was assessed using Begg’s funnel
plots and Egger’s regression test at the P,0·10 level of signifi-
cance(22). In case of publication bias, a non-parametric ‘trim
and fill’ method was used to adjust for this bias(23). Alterna-
tively, we performed a sensitivity analysis in which smaller
studies that reported more extreme effect sizes were excluded.
All analyses were performed using STATA version 11.0 (Stata-
Corp). P values ,0·05 were considered statistically significant,
except where otherwise specified.
Results
Literature search
Fig. 1 shows the flow of the literature search. An initial search
of the three electronic databases identified 235 records, of
which the majority were excluded based on title and abstract
scan, leaving twenty-seven articles for full-text review. Of
these articles, fourteen were excluded because they used
enzymatically hydrolysed milk or other fermented milk pro-
ducts rather than probiotic fermented milk as the intervention
product, had a co-intervention of other supplementations,
measured acute effect only or were duplicate reports from
the same trial (detailed reasons for the exclusion of these
fourteen articles are given in Table S1, available online).
Finally, thirteen articles (fourteen trials) were selected for
the final analysis.
Study characteristics
The characteristics of studies and participants for the fourteen
trials are given in Table 1. The trials were published between
1996 and 2010. Of the fourteen trials, eight were conducted in
European countries and the remaining in Japan. The sample
size varied from 20 to 108, with a sum of 702 and a median
of 40. The treatment was double blind in eleven trials, single
blind in two trials and open label in the remaining one
trial. All trials but one had a parallel design. The duration of
intervention was from 4 to 24 weeks, with a median of
8 weeks. The dose of probiotic fermented milk varied from
100 to 450 g/d, and most of the control groups received a
milk-based placebo product (e.g. artificially acidified milk).
In eight trials, all participants were hypertensive patients; in
three trials, patients used antihypertensive medications.
Study quality differed across the trials (Table SII, available
online). All trials reported random allocation, but few of
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them reported details of sequence generation and allocation
concealment. In nine trials, dropout reasons along with num-
bers were mentioned. Another three trials analysed data
according to an intention-to-treat principle.
Main analysis
Of the fourteen trials, thirteen reported a reduction in systolic
BP after probiotic fermented milk intervention, with mean net
changes ranging from 21·5 to 212·4 mmHg. Compared with
the control, the pooled effect size was 23·10 mmHg (95 %
CI 24·64, 21·56) for systolic BP (Fig. 2), with no evidence
of heterogeneity between the trials (P¼0·19 and I 2 ¼ 24·1 %).
Of the thirteen trials, one trial(7) reported data for systolic
BP only and eleven trials reported a reduction in diastolic
BP after probiotic fermented milk consumption, with mean
net changes ranging from 20·3 to 26·5 mmHg. The pooled
effect size was 21·09 mmHg (95 % CI 22·11, 20·06) for dias-
tolic BP (Fig. 3), without an indication of heterogeneity
(P¼0·15 and I 2 ¼ 29 %).
Subgroup and sensitivity analyses
Table 2 presents the results of subgroup analyses according
to hypertension status, study location and duration of interven-
tion. Hypertensive participants, compared with normotensive
ones, experienced a greater reduction in systolic BP (23·98 v.
22·09 mmHg). Trials conducted in Japan, compared with
those carried out in European countries, showed a markedly
greater reduction in both systolic BP (26·12 v. 22·08 mmHg)
and diastolic BP (23·45 v. 20·52 mmHg).
Table 3 presents the results of sensitivity analyses limited to
parallel trials, double-blind trials and trials excluding parti-
cipants using antihypertensive medications. In general, the
results were similar with the overall combined effect sizes.
Repeated analyses examining the impact of a single trial on
the overall results by omitting one trial in each turn yielded
a range from 23·64 mmHg (95 % CI 25·25, 22·03) to
22·68 mmHg (95 % CI 24·26, 21·11) for systolic BP and
from 20·90 mmHg (95 % CI 21·95, 0·15) to 21·64 mmHg
(95 % CI 22·76, 20·47) for diastolic BP.
Publication bias
Visual inspection of Begg’s funnel plots showed some asym-
metry, and Egger’s test suggested evidence of publication
bias (P¼0·02 for systolic BP and P¼0·002 for diastolic BP).
However, in a sensitivity analysis using a non-parametric
‘trim and fill’ method, no study was removed and the overall
effect size remained unchanged. When small trials showing
more extreme results were excluded(6,9,13), the pooled effect
size was slightly attenuated to 22·26 mmHg (95 % CI 23·88,
20·64) for systolic BP and 20·69 mmHg (95 % CI 21·76,
235 records identified for title abstract scan
Twenty-seven articles identified for full-text review
Thirteen articles accepted for meta-analysis
Fourteen articles excluded
   Duplicate reports
   Combined intervention
   Not probiotic fermented milk
   Acute effect only
208 articles excluded
    Reviews or letters
    Observational studies
    Animal experiments
    Not relevant intervention
    Not relevant outcome
Fig. 1. Flow chart of the study selection.
Table 1. Characteristics of clinical trials examining the effect of probiotic fermented milk on blood pressure (BP)
Study Location Design
Duration
(weeks)
Dose
(ml/d) Age
Sex
(M/F)
Baseline BP
(mmHg)
Antihypertensive
drug use
Hata (1996)(6) Japan R, PC, P 8 100 75 8/22 159/89 v. 151/87 Yes
Agerholm-Larsen (2000)(7) Denmark R, PC, DB, P 8 450 39 9/21 121/79 v. 117/76 No
Kawase (2000)(8) Japan R, PC, SB, P 8 400 40·1 20/0 124/– v. 124/– No
Inoue (2003)(9) Japan R, PC, SB, P 12 100 55 20/15 155/93 v. 150/93 No
Seppo (2003)(10) Finland R, PC, DB, P 21 150 49·6 19/20 155/97 v. 152/96 Yes
Mizushima (2004)(11) Japan R, PC, DB, P 4 160 46·4 46/0 148/93 v. 145/92 No
Tuomilehto (2004)(12) Finland R, PC, DB, P 10 150 52·7 36/24 153/98 v. 157/98 No
Aihara (2005)(13) Japan R, PC, DB, P 4 150 51·5 26/14 137/85 v. 137/85 No
Aihara (2005)(13) Japan R, PC, DB, P 4 150 51·5 32/8 147/92 v. 149/93 No
Jauhiainen (2005)(14) Finland R, PC, DB, P 10 300 53 36/72 149/94 v. 150/93 No
Engberink (2008)(15) The Netherlands R, PC, DB, P 8 200 58·8 43/24 142/83 v. 141/84 Yes
van der Zander (2008)(16) The Netherlands R, PC, DB, X 4 250 35–70 42 130/81 v. 128/81 No
Jauhiainen (2010)(17) Finland R, PC, DB, P 24 400 49 54/35 155/94 v. 151/95 No
Usinger (2010)(18) Denmark R, PC, DB, P 8 300 55 29/30 134/95 v. 134/94 No
M, male; F, female; R, randomised; PC, placebo controlled; P, parallel; DB, double blind; SB, single blind; –, no information available; X, cross-over.
J.-Y. Dong et al.1190
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0·39) for diastolic BP. As indicated by Egger’s test, publication
bias disappeared for systolic BP (P¼0·39), but it may remain
for diastolic BP (P¼0·06).
Discussion
The present meta-analysis systematically examined the effect
of probiotic fermented milk on BP. Findings from the present
study showed that probiotic fermented milk, compared
with placebo, produced a significant reduction of 3 mmHg
in systolic BP and 1 mmHg in diastolic BP. The magnitudes
of BP reductions reported herein are modest. However, on a
population level, even a small reduction in BP could have
important public health consequences; a 2 mmHg decrease
in systolic BP has been shown to be associated with 10 %
lower stroke mortality and 7 % lower CHD mortality(24).
We observed that probiotic fermented milk had a slightly
greater effect on systolic BP in hypertensive participants
than in normotensive ones (23·98 v. 22·09 mmHg). This
highlights the potential role of probiotic fermented milk in
the control and treatment of hypertension. The Dietary
Approaches to Stop Hypertension trial demonstrated that a
dietary pattern abundant in fruits, vegetables and low-fat
dairy products can considerably reduce BP(25). Data from
Study
Net
change 95% CI Weight (%)
Hata (1996)(6)
Agerholm-Larsen (2000)(7)
Kawase (2000)(8)
Inoue (2003)(9)
Seppo (2003)(10)
Mizushima (2004)(11)
Tuomilehto (2004)(12)
Aihara (2005) (normotensive)(13)
Aihara (2005) (hypertensive)(13)
Jauhiainen (2005)(14)
Engberink (2008)(15)
van der Zander (2008)(16)
Jauhiainen (2010)(17)
Usinger (2010)(18)
–25 –20 –15 –10 –5 0 5 10
Change in systolic blood pressure (mmHg)
Overall (I2 = 24·1 % P = 0·193)
–9·70 –19·03, –0·37
–2·20 –7·52, 3·12
–6·90 –17·01, 3.21
–12·40 –23·36, –1·44
–5·00 –10·87, 0·87
–1·50 –7·89, 4·89
–2·30 –8·71, 4·11
–3·20 –8·78, 2·38
–11·20 –18·14, –4·26
–2·00 –5·93, 1·93
2·80  –2·50, 8·10
–1·70 –6·70, 3·30
–2·00 –6·81, 2·81
–4·40 –9·15, 0·35
–3·10 –4·63, –1·56
2·72
8·34
2·31
1·96
6·85
5·78
5·75
7·59
4·90
15·25
8·42
9·46
10·19
10·48
100·00
Fig. 2. Meta-analysis of the effect of probiotic fermented milk on systolic blood pressure when compared with placebo.
Study
Net
change  95% CI Weight (%)
Hata (1996)(6)
Agerholm-Larsen (2000)(7)
Inoue (2003)(9)
Seppo (2003)(10)
Mizushima (2004)(11)
Tuomilehto (2004)(12)
Aihara (2005) (normotensive)(13)
Aihara (2005) (hypertensive)(13)
Jauhiainen (2005)(14)
Jauhiainen (2010)(17)
Usinger (2010)(18)
–15 –10 –5 0
Change in diastolic blood pressure (mmHg)
5 10
Overall (I2 = 29.0 % P = 0.153)
Engberink (2008)(15)
van der Zander (2008)(16)
–4.40 –10.57, 1.77
–1.90 –5.79, 1.99
–1.40 –6.12, 3.32
–2.50 –6.01, 1.01
–1.70 –6.44, 3.04
–0.50 –4.09, 3.09
–5.00 –9.77, –0.23
–6.50 –12.82, –0.18
1.00 –1.28, 3.28
–2.00 –4.92, 0.92
–4.80 –10.31, 0.71
–1.09 –2.11, –0.06
2.20 –1.09, 5.49
–0.30 –3.37, 2.77
2.76
6.95
4.73
8.53
4.68
8.18
4.62
2.63
20.18
12.37
3.46
100.00
9.73
11.17
Fig. 3. Meta-analysis of the effect of probiotic fermented milk on diastolic blood pressure when compared with placebo.
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the present study provide further support for an important
role of probiotic fermented milk in the Dietary Approaches
to Stop Hypertension diet. Also, a recent finding based on
the Framingham Heart Study Offspring Cohort has demon-
strated that normotensive adults who had a high intake of
yogurt (.2 % of total daily energy intake) were 31 % less
likely to develop incident hypertension over 15 years(26).
Another interesting finding of the present meta-analysis
was that study location (Japan v. European countries) may
modify the effect of probiotic fermented milk on BP. Analysis
of trials conducted in Japan showed a greater reduction
than those conducted in European countries for both
systolic BP (26·12 v. 22·08 mmHg) and diastolic BP (23·45
v. 20·52 mmHg). The average intake of dairy foods in the
Japanese population is lower than that in Western popu-
lations, and hence the intervention markedly enhanced
their milk intake, especially fermented milk intake, which
might explain the pronounced hypotensive effect observed
in Japanese trials(27). Alternatively, the weaker methodology
used in some Japanese trials (e.g. insufficient blinding)
might have overestimated the true effect of the treatment.
A similar observation was also made for the BP-lowering
effect of lactotripeptide consumption among Japanese,
Finland and Netherlandish studies(28), and ethnic difference
in genetic disposition has been suggested to contribute to
various degrees of hypertension(29). However, due to a limited
number of trials being performed to date, it is still inconclusive
to confirm the role of genotype polymorphism in the under-
lying BP-lowering mechanism in the present study.
Several functional components in probiotic fermented
milk may account for the BP-lowering effects. It is also
possible that different fermented milk products act via
different mechanisms or that a single product acts via mul-
tiple mechanisms. Two tripeptides, valine–proline–proline
and isoleucine–proline–proline, have been extensively
studied(30), and, indeed, many products used in the trials
included in the present meta-analysis contained them. These
tripeptides exert angiotensin-converting enzyme inhibitory
activity in vitro and are hypothesised to lower BP through
this mechanism(31). In fact, two recent meta-analyses of
clinical trials have documented mild BP-lowering effects
of valine–proline–proline and isoleucine–proline–proline
interventions(30,32), although the summary effect sizes were
relatively weaker in the latter one(32). The fermented product
used in the study carried out by Inoue et al.(9), however,
exhibited no angiotensin-converting enzyme-inhibiting acti-
vity. Instead, the authors attributed the BP-lowering effect
to the presence of g-aminobutyric acid, where the test product
contained 10–12 mg/ml, which has been shown to lower BP
when administered orally to human subjects(33).
Probiotic micro-organisms found in fermented milk, such as
Lactobacillus helveticus and L. acidophilus, may influence gut
microbiota composition, which is suggested to have an impact
on the development of metabolic disorders(34). It has also
been suggested that bacterial cell wall fragments may have
an antihypertensive effect(35,36). Indeed, studies examined in
the present meta-analysis used live micro-organisms in
addition to the fermented base and, thus, the effect could
have been at least partially attributable to them. However,
in the Aihara et al.(13) study, the test product displayed
BP-lowering effects despite being depleted of bacterial frag-
ments. In addition, no studies on the effect of pure probiotic
biomass on BP in human subjects have been published. One
study has investigated the effect of fermented rosehip drink
Table 2. Subgroup analyses according to hypertension status, study location and duration of intervention
Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg)
Groups Trials (n)
Net
change 95 % CI Pheterogeneity I
2 (%) Trials (n)
Net
change 95 % CI Pheterogeneity I
2 (%)
Total 14 23·10 24·64, 21·56 0·19 24·1 13 21·09 22·11, 20·06 0·15 29
Hypertension
Yes 8 23·98 26·08, 21·88 0·17 33 8 21·15 22·43, 0·13 0·31 15·8
No 6 22·09 24·34, 0·17 0·39 4·4 5 21·45 24·04, 1·14 0·07 53·3
Location
Europe 8 22·08 23·86, 20·30 0·64 0 8 20·52 21·66, 0·62 0·23 25·2
Japan 6 26·12 29·17, 23·06 0·22 28·2 5 23·45 25·77, 21·12 0·62 0
Duration
# 8 weeks 9 23·43 26·07, 20·79 0·1 40·3 8 22·09 24·17, 20·01 0·1 42·6
. 8 weeks 5 23·07 25·50, 20·64 0·44 0 5 20·68 22·07, 0·72 0·41 0
Table 3. Sensitivity analyses restricted to certain trials
Systolic blood pressure (mmHg) Diastolic blood pressure (mmHg)
Restriction Trials (n)
Net
change 95 % CI Pheterogeneity I
2 (%) Trials (n)
Net
change 95 % CI Pheterogeneity I
2 (%)
Parallel 13 23·24 24·86, 21·63 0·16 28·6 12 21·19 22·27, 20·10 0·12 33·8
Double-blinding 11 22·62 24·21, 21·02 0·32 13·4 11 20·97 22·04, 0·09 0·11 36·4
No use of
antihypertensive
drugs
11 23·33 25·02, 21·63 0·44 0 10 21·22 22·38, 20·07 0·26 20·2
J.-Y. Dong et al.1192
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on BP, but this product, similar to fermented milk, comprised
the fermented matrix and the fermenting micro-organisms,
both with potential functional contributions(37). Finally, some
of the BP-lowering effects of fermented milk may derive
from the mineral content of milk products, including K, Ca
and P, proposed to exhibit an antihypertensive activity(38).
However, the observed BP-lowering effects were probably
not due to these minerals, because they were well balanced
between the intervention and control groups in most trials.
To date, several prospective cohort studies have examined
the association between fermented milk (mainly yogurt) con-
sumption and the risk of developing hypertension(39–42). All
these studies have shown an inverse relationship with the rela-
tive risk, which ranged from 0·85 to 0·97, but none of them
reached statistical significance. We hence combined these
data and obtained a summary relative risk of 0·91 (95 % CI
0·84, 1·00; P¼0·04), indicating that higher intake of yogurt,
compared with lower intake, was associated with a 9 %
reduced risk of developing hypertension. Therefore, the find-
ings of the present meta-analysis of randomised controlled
trials are in line with those from cohort studies, both support-
ing a hypotensive effect of fermented milk.
The major strength of the present study is that all the
included trials had a randomised, placebo-controlled design.
Such a design minimises the risk of confounding bias, which
is of great concern in observational studies. In addition,
using a meta-analysis approach, we enlarged the sample size
and hence increased the statistical power. However, potential
limitations involved in either primary studies or the present
meta-analysis should be considered while interpreting the
findings. First, we included only published studies in the
meta-analysis, raising the risk of publication bias. Funnel
plots for both systolic BP and diastolic BP showed evidence
of possible bias, favouring the publication of small trials
with extreme effects. However, these trials had small weights
in the present meta-analysis and excluding them from the
analysis led to only a slight attenuation of the effect on systolic
BP. Second, as with any meta-analysis, the validity depended
upon the quality of primary studies. Although all trials were
randomised and placebo controlled, the study quality varied;
for example, the lack of double-blinding in several trials
increased the risk of expectation bias(6,8,9). Nevertheless, sen-
sitivity analyses limited to double-blind trials yielded similar
results. Third, most trials had a relatively small sample size
(n ,60) and short treatment duration (,3 months). As has
been mentioned previously, small studies with more extreme
results may have increased the risk of publication bias, posing
a potential threat to the validity of the present meta-analysis.
Because of the short duration, whether the findings could
translate into a long-term treatment effect is uncertain.
Conclusion
In summary, the present meta-analysis suggested that probio-
tic fermented milk has BP-lowering effects in pre-hypertensive
and hypertensive subjects. However, while the role of fer-
mented milk bioactives in BP lowering is well studied, the
potential contribution to BP lowering by live micro-organisms
exerting a probiotic effect remains to be elucidated in
human subjects. Consequently, for the time being, the term
‘probiotic’, defined as ‘live microorganisms which when
administered in adequate amounts confer a health benefit
on the host’, is best avoided in connection with BP-lowering
fermented milk. Well-designed, large-scale trials are required
to confirm these findings.
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